SGT 1001
Alternative Names: SGT-1001Latest Information Update: 07 Jun 2024
At a glance
- Originator SalioGen Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action ATP binding cassette transporter subfamily A member 4 replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Stargardt disease
Most Recent Events
- 23 Apr 2024 SGT 1001 is available for licensing as of 23 Apr 2024. https://www.saliogen.com/partnering/
- 17 Apr 2024 Preclinical trials in Stargardt disease in USA (Ophthalmic) prior to April 2024
- 17 Apr 2024 Pharmacodynamics data from a preclinical study in Stargardt disease released by SalioGen Therapeutics